EDIT — Editas Medicine Share News
0.000.00%
Last trade - 00:00- $382.41m
- $226.51m
- $40.52m
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering
NASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Editas Medicine tumbles after launching equity offering
Brief: Editas Medicine Reports New Preclinical Data Demonstrating Progress Of Edit-401 As Potential Treatment For Hyperlipidemia
Editas Medicine Q1 net loss narrows
Brief: Editas Medicine Q1 Net Income USD -24.982 Million Vs. IBES Estimate USD -26.5 Million
Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: Editas Medicine Q4 Net Income USD -5.62 Million Vs. IBES Estimate USD -24.3 Million
Editas Medicine Q3 net loss narrows, beats expectations
Brief: Editas Medicine Q3 Net Income USD -25.117 Million Vs. IBES Estimate USD -28.1 Million
Brief: Editas Medicine Inc - Nominates Edit-401 As Lead In Vivo Candidate
Editas Medicine posts Q2 net loss of $53.2 mln
Editas Medicine Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas’ Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting
Editas Medicine Inc reports results for the quarter ended March 31 - Earnings Summary